Geneoscopy has developed a novel methodology to reliably and consistently extract stool-derived eukaryotic RNA (seRNA) transcripts and detect changes in gene expression. This provides Geneoscopy a platform to harness the power of seRNA to detect, prevent, and guide treatment for gastrointestinal disease. Geneoscopy is currently developing a diagnostic test for the detection and prevention of colorectal cancer in human and a diagnostic test to differentiate GI lymphoma from inflammatory bowel disease (IBD) in cats. Geneoscopy is also exploring the use of its technology for other gastrointestinal applications in both humans and animals.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/02/19 | $6,900,000 | Series A |
Cultivation Capital Lightchain Capital NT Investments | undisclosed |
